Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Utidelone plus pembrolizumab as the fourth-line combination treatment in non-small cell lung cancer with EGFR mutation: a case report.

Anti-cancer drugs - 1 Jan 2025

Fang Henghu, Yang Wei, Han Qing, Zhao Rugang, Zheng Wei, Lu Zejun, Wu Shanshan, Zhu Qi, Li Jingjiao, Guan Gaowa, Wen Juyi

Abstract excerpt

Utidelone is an ebomycin derivative chemotherapeutic drug, which can promote tubulin polymerization and stabilize microtubule structure, so as to induce apoptosis. The drug is an innovative drug independently developed by China with independent intellectual property rights. Phase II clinical trials for advanced breast cancer are being approved by National Medical Products Administration for the treatment of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 39423045
DOI: 10.1097/CAD.0000000000001661

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Utidelone plus pembrolizumab as the fourth-line combination treatment in non-small cell lung cancer with EGFR mutation: a case report.PMID 39423045Read ↗

Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.Semantic proximity Read ↗

Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.Semantic proximity Read ↗

Bevacizumab plus dacomitinib combination therapy for L858R-mutated metastatic lung adenocarcinoma: A report of two cases.Semantic proximity Read ↗

Cevipabulin-tubulin complex reveals a novel agent binding site on α-tubulin with tubulin degradation effectSemantic proximity Read ↗

[Antibody therapy in cancer].Semantic proximity Read ↗

Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report.Semantic proximity Read ↗

A review of research progress of antitumor drugs based on tubulin targetsSemantic proximity Read ↗

A phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesotheliomaSemantic proximity Read ↗

Class III β-Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized TrialSemantic proximity Read ↗

Osimertinib for the Treatment of EGFR Mutation-Positive Lung Adenocarcinoma Complicated With Dermatomyositis.Semantic proximity Read ↗

Novel Drugs Targeting Microtubules: the Role of EpothilonesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.